Drug Trial Radar · NCT00560755
Safety Study of ProQuad® rHA in Infants (V221-037)
Last checked: Nov 20, 2026Latest source record: Oct 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,388
Actual
Start
Oct 24, 2007
Primary completion
Nov 24, 2008
Study completion Nov 24, 2008
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 20, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 22 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life. Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.
Conditions
- Measles
- Mumps
- Rubella
- Varicella
Interventions
ProQuad®Biological
ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2Time frame: Up to Day 46 (for 4 days following ProQuad® Dose 2)
- Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2Time frame: Up to Day 70 (up to 28 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2Time frame: Up to Day 84 (up to 42 days after ProQuad® Dose 2)
- Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2Time frame: Up to Day 84 (up to 42 days after ProQuad® Dose 2)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.